Reported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Cibus, Inc.
Report date March 01, 2023 · Filed June 01, 2023
Section 16 reporting ended · disclosed 2023-06-01. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-03-01 · Disposition to issuer · Disposed 25,000 · Balance 0 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.55 · Expires 2030-08-04 | Direct | 25,000 |
Reported balance
After 2023-03-01 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-03-01 · Grant · Acquired 25,000 · Balance 25,000 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-03-01 · Disposition to issuer · Disposed 10,291 · Balance 0 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.22 · Expires 2031-05-27 | Direct | 10,291 |
Reported balance
After 2023-03-01 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-03-01 · Grant · Acquired 10,291 · Balance 10,291 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 0 |
Reported balance
After 2023-03-01 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-03-01 · Disposition to issuer · Disposed 47,200 · Balance 0 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
| Stock Option (Right-to-Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.30 · Expires 2032-06-13 | Direct | 47,200 |
Reported balance
After 2023-03-01 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-03-01 · Grant · Acquired 47,200 · Balance 47,200 F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. |
Filing footnotes · ownership attribution and instrument terms
F1: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 47,200 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 6 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 47,200 Underlying: Common Stock · 47,200 shares Expires 2032-06-13 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 47,200 | Not disclosed Strike: $0.30 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 5 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 47,200 shares Expires 2032-06-13 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 10,291 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 4 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,291 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 10,291 | Not disclosed Strike: $4.22 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 3 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 25,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-04 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| March 01, 2023 Filed Jun 1, 2023 19:23 UTC | Cibus, Inc. CLXT · Entity 6658 | Disposition to issuerStock Option (Right-to-Buy) · Derivative | 25,000 | Not disclosed Strike: $4.55 | Not disclosed |
DisclosureSEC source: 0001615594-23-000037 · primary_doc.xml · derivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 25,000 shares Expires 2030-08-04 F1 · kind: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · price: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. F1 · derivative.exercise_date: Teh reported transactions reflect a March 1, 2023 material modification of an outstanding stock option with a 90-day post-separation exercise period to extend the exercise period from 90 days to five years from the date of grant. Calyxt, Inc. effected a one-for-ten reverse stock split of its common stock effective on April 24, 2023 and a one-for-five reverse stock split of its common stock on May 31, 2023. Amounts reported above are pre-split. Read SEC document |
| September 19, 2022 Filed Sep 20, 2022 16:09 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 30,000 | $0.24 | $7,173.00 |
DisclosureSEC source: 0001615594-22-000049 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 99,225 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on September 21, 2021. F2 · shares: The price reported in Column 4 is a weighted average. The shares were sold in multiple transactions at prices ranging from $.2300 to $.2506, inclusive. Read SEC document |
| June 13, 2022 Filed Jun 15, 2022 16:19 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 47,200 | $0.00 Strike: $0.30 | $0.00 |
DisclosureSEC source: 0001615594-22-000038 · primary_doc.xml · derivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,200 Underlying: Common Stock · 47,200 shares Expires 2032-06-13 F1 · derivative.exercise_date: Option vests in full on the first anniversary of the date of the grant. Read SEC document |
| March 21, 2022 Filed Mar 22, 2022 16:09 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 20,000 | $1.06 | $21,238.00 |
DisclosureSEC source: 0001615594-22-000016 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,225 F1 · kind: The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on September 21, 2021. F2 · price: The price reported in Column 4 is a weighted average. The shares were sold in multiple transactions at prices ranging from $1.04 to $1.14, inclusive. Read SEC document |
| July 27, 2021 Filed Jul 28, 2021 17:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 50,429 | $3.65 | $184,065.85 |
DisclosureSEC source: 0001615594-21-000079 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 149,225 F1 · shares: The Restricted Stock Units vest as to one-third (1/3) on the date of the grant; one-third (1/3) on the six-month anniversary of the date of the grant; and the remaining one-third (1/3) on the one-year anniversary of the date of the grant. Read SEC document |
| July 01, 2021 Filed Jul 6, 2021 16:59 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 12,048 | $4.07 | $49,035.36 |
DisclosureSEC source: 0001615594-21-000074 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 98,796 F1 · shares: The Restricted Stock Units vest as to one-third (1/3) on the effective date of an employment agreement appointing a permanent Chief Executive Officer (the "CEO Start Date"); one-third (1/3) on the six-month anniversary of the CEO Start Date; and the remainder shall vest on the one-year anniversary of the CEO Start Date. Read SEC document |
| June 01, 2021 Filed Jun 2, 2021 16:58 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 11,967 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000069 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,748 F1 · shares: The Restricted Stock Units vest as to one-third (1/3) on the effective date of an employment agreement appointing a permanent Chief Executive Officer (the "CEO Start Date"); one-third (1/3) on the six-month anniversary of the CEO Start Date; and the remainder shall vest on the one-year anniversary of the CEO Start Date. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 17:42 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 10,291 | $0.00 Strike: $4.22 | $0.00 |
DisclosureSEC source: 0001615594-21-000067 · primary_doc.xml · derivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,291 Underlying: Common Stock · 10,291 shares Expires 2031-05-27 F2 · derivative.exercise_date: Option vests in full on 5/27/2022. Read SEC document |
| May 27, 2021 Filed Jun 1, 2021 17:42 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 18,730 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000067 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,781 F1 · shares: The Restricted Stock Units vest in full on 5/27/2022. Read SEC document |
| May 03, 2021 Filed May 5, 2021 16:51 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 9,430 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000048 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director · Executive Chair 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,051 F1 · shares: The Restricted Stock Units vest as to one-third (1/3) on the effective date of an employment agreement appointing a permanent Chief Executive Officer (the "CEO Start Date"); one-third (1/3) on the six-month anniversary of the CEO Start Date; and the remainder shall vest on the one-year anniversary of the CEO Start Date. Read SEC document |
| April 01, 2021 Filed Apr 2, 2021 16:43 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantCommon Stock | 16,591 | $0.00 | $0.00 |
DisclosureSEC source: 0001615594-21-000042 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,621 F1 · shares: The Restricted Stock Units reported on this Form 4 vest as to 1/3 of the shares on the effective date of an employment agreement appointing a permanent Chief Executive Officer of the Issuer (the "CEO Start Date"); 1/3 on the six-month anniversary of the CEO Start Date; and 1/3 on the one-year anniversary of the CEO Start Date. Read SEC document |
| August 04, 2020 Filed Aug 7, 2020 19:09 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right-to-Buy) · Derivative | 25,000 | $0.00 Strike: $4.55 | $0.00 |
DisclosureSEC source: 0001615594-20-000058 · primary_doc.xml · derivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-08-04 F1 · derivative.exercise_date: Option vests as to 1/3 of the shares on each of the first three anniversaries of the date of the grant. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 400 | $5.54 | $2,216.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 14 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,030 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 302 | $5.51 | $1,664.02 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 13 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,430 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,700 | $5.50 | $9,350.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 12 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,732 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 602 | $5.48 | $3,298.96 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 11 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,432 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 700 | $5.47 | $3,829.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 10 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,034 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,100 | $5.46 | $6,006.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 9 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,734 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 300 | $5.46 | $1,636.50 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 8 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,834 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 802 | $5.45 | $4,370.90 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 7 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,134 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 890 | $5.44 | $4,841.60 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 6 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,936 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 200 | $5.44 | $1,087.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 5 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 36,826 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 894 | $5.43 | $4,854.42 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 4 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,026 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 200 | $5.43 | $1,085.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 3 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,920 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 200 | $5.42 | $1,084.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,120 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| February 28, 2020 Filed Mar 2, 2020 10:45 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleCommon Stock | 1,700 | $5.41 | $9,197.00 |
DisclosureSEC source: 0001615594-20-000016 · primary_doc.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,320 F1 · kind: The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by reporting person on December 4, 2018. Read SEC document |
| May 06, 2019 Filed May 8, 2019 20:38 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 7,500 | $0.00 Strike: $15.59 | $0.00 |
DisclosureSEC source: 0001127602-19-017806 · form4.xml · derivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,500 Underlying: Common Stock · 7,500 shares Expires 2029-05-06 F1 · derivative.exercise_date: The stock option to purchase shares of Calyxt, Inc. common stock ("Stock Option") was granted on May 6, 2019 and vests 15% on May 6, 2020 and 15% on May 6, 2021, with the remainder vesting quarterly (commencing with the third fiscal quarter of 2021) in equal installments over 42 months. Read SEC document |
| March 14, 2019 Filed Mar 15, 2019 16:01 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleRestricted Stock Units | 4,980 | $16.33 | $81,317.42 |
DisclosureSEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 4 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,020 F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020. F5 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.82 to $16.85, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (5) to this Form 4. Read SEC document |
| March 13, 2019 Filed Mar 15, 2019 16:01 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleRestricted Stock Units | 5,000 | $16.08 | $80,410.00 |
DisclosureSEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 3 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,000 F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $15.76 to $16.365, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (4) to this Form 4. Read SEC document |
| March 12, 2019 Filed Mar 15, 2019 16:01 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleRestricted Stock Units | 5,000 | $16.76 | $83,819.00 |
DisclosureSEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $16.19 to $16.99, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (3) to this Form 4. Read SEC document |
| March 11, 2019 Filed Mar 15, 2019 16:01 UTC | Cibus, Inc. CLXT · Entity 6658 | SaleRestricted Stock Units | 5,000 | $17.39 | $86,957.50 |
DisclosureSEC source: 0001127602-19-011543 · form4.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,000 F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vested 33.3% on October 10, 2018, with 33.3% vesting on October 10, 2019, and 33.4% vesting on October 10, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $17.665 to $17.79, inclusive. The reporting person undertakes to provide Calyxt, Inc., any security holder of Calyxt, Inc., or the staff of the SEC, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4. Read SEC document |
| August 21, 2018 Filed Oct 10, 2018 17:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantStock Option (Right to Buy) · Derivative | 180,000 | $0.00 Strike: $17.10 | $0.00 |
DisclosureSEC source: 0001127602-18-029914 · form4.xml · derivative · entry 2 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 180,000 Underlying: Common Stock · 180,000 shares Expires 2028-08-21 F2 · derivative.exercise_date: The Stock Option was granted on August 21, 2018 and vests 33.3% on January 1, 2019, 33.3% on January 1, 2020, and 33.4% vesting on January 1, 2021. Read SEC document |
| August 21, 2018 Filed Oct 10, 2018 17:23 UTC | Cibus, Inc. CLXT · Entity 6658 | GrantRestricted Stock Units | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001127602-18-029914 · form4.xml · nonDerivative · entry 1 Ribeill Yves J · CIK 0001604049 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 F1 · security: The award of restricted stock units with respect to Calyxt, Inc. common stock was granted on August 21, 2018 and vests 33.3% on January 1, 2019, 33.3% on January 1, 2020, and 33.4% vesting on January 1, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.